Australian Advantage

Australia offers a world-class environment for manufacturing and clinical trials, delivering exceptional quality, accelerated timelines, and cost-efficient solutions within a leading clinical and medical ecosystem. IDT Australia is your ideal CDMO partner, combining these advantages with proven GMP end-to-end expertise across APIs, specialty orals, and sterile fill–finish to support seamless development and manufacturing.

Why Australia

Quality

Australia is known for its stringent quality standards, strong clinical trial ecosystem, and skilled workforce.

Cost

Eligible R&D performed in Australia may attract a refundable 43.5% offset for smaller companies, and a non-refundable offset for larger organisations, subject to current program settings.

Speed and Efficiency

Australia’s CTN and CTA frameworks streamline trial start-up. Once ethics (HREC) and site approvals are in place, studies can begin immediately, without waiting for separate TGA review, enabling faster first-patient-in timelines.

Business Stability and Risk Mitigation

Low political risk, strong IP enforcement, and reliable supply chains make Australia a safe and predictable base for long-term programs.

Diverse, Multicultural population

Australia’s multicultural population enables recruitment of participants from a variety of ethnic backgrounds, supporting robust, globally relevant clinical data that can strengthen submissions to international regulators.

Strong Collaboration Opportunities

Close links with universities, research institutes, CROs, and government programs foster innovation and make partnerships easier.

Unlock a 43.5% cash refund on eligible R&D

Looking to boost your R&D budget? Through the Australian Government’s R&D Tax Incentive, projects conducted with IDT Australia may be eligible for a 43.5% refundable tax offset. As a registered Research Service Provider (RSP), if your project is eligible, we make it easy to access this benefit, while providing expert support across every stage of your pharmaceutical development.

What it means for you

Faster study starts and smoother transfers

Clinical data generated in Australia is recognised by major regulators including the FDA, EMA, and TGA, supporting faster approvals worldwide

Reliable, end-to-end support – benefit from IDT Australia’s proven GMP capability across APIs, specialty orals, and sterile fill–finish on a single site.

Let’s plan your pathway.

Start your program with confidence – speak with our team today to explore your API, oral dose, aseptic, or advanced therapy options

Talk to an expert